Tatiana Kekeeva

Dr. Tatiana Kekeeva


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MAMaria Akhkiamova
Maria Akhkiamova
AMAndrey Marakhonov
Andrey Marakhonov
VZVictoria V. Zabnenkova
Victoria V. Zabnenkova
KMKristina Mikhalchuk
Kristina Mikhalchuk
SVSergei V. Voronin
Sergei V. Voronin
Olga ShchaginaOlga Shchagina
Olga Shchagina
Since 2023, the Russian Federation (RF) has implemented an expanded newborn screening (NBS) program for 36 hereditary disorders, which now includes 5q spinal muscular atrophy (5q SMA). As a result of newborn screening for 5q SMA conducted in the RF during 2023–2024, 288 newborns with a homozygous deletion of exon 7 in the SMN1 gene were identified by molecular genetic methods. The overall observed incidence of 5q SMA was 1 in 8439 newborns, which does not significantly differ from the expected incidence of 1 in 7953 newborns, established by previous pilot screening projects (p > 0.05). A comparison of the genotypes of patients identified through selective and newborn screening showed statistically significant differences in the proportions of patients carrying two, three, and four or more copies of the SMN2 gene. These findings demonstrate that the NBS program is effective in detecting both individuals with more severe phenotypes, as expected, and those with milder forms of the disease.

11 April 2024 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
MLM.E. Leontyeva
M.E. Leontyeva
MHMoscow Morozov Children’s City Clinical Hospital
Moscow Morozov Children’s City Clinical Hospital
EKE.I. Kovtun
E.I. Kovtun
SZS.B. Zimin
S.B. Zimin
GBG.O. Bronin
G.O. Bronin
MEMoscow Russian Medical Academy For Continuous Professional Education
Moscow Russian Medical Academy For Continuous Professional Education

29 December 2024 in Russian Medicine
Verified
Journal Article
Open access
VZVers V. Zarubina
Vers V. Zarubina
OVOlga V. Vysokolova
Olga V. Vysokolova
MMMariya A. Mukhina
Mariya A. Mukhina
EYElena E. Yakushina
Elena E. Yakushina
TKTatiana Kekeeva
Tatiana Kekeeva
МАМухина Мария Алексеевна
Мухина Мария Алексеевна
BACKGROUND: The nutritional status of patients with cystic fibrosis significantly affects their survival and the function of all organs, particularly the lungs. Due to increased protein and energy needs, these patients often require high-calorie and high-protein oral nutritional supplements (ONS). AIM: To assess the tolerability, efficacy, and safety of the ONS containing whey protein and soy lecithin. MATERIALS AND METHODS: The data of 14 patients with mixed form of cystic fibrosis and nutritional deficiencies, aged between 6 and 16 years, were analyzed. Five patients received ONS containing whey protein and soy lecithin (Fresubin Protein®) as monotherapy (Group 1), four patients received the same therapeutic food together with emulsion of medium-chain triglycerides (Group 2), and five patients received ONS balanced in protein, fat, and carbohydrates (control group). The dynamics between percentile and Z-Scores of body mass index (BMI) at the beginning and at the end of the study period (day 180±2) were used as the main efficacy parameter of the investigated food. Body fat and lean body mass were assessed by caliperometry as additional efficacy parameters. RESULTS: All patients showed an increase in Z-Score and BMI percentile from baseline while taking ONS containing whey protein and soy lecithin both as monotherapy and in combination with medium-chain triglyceride emulsion. There were no statistically significant differences from the control group (p 0.05). However, Group 1 (100% of patients) demonstrated positive changes in muscle mass gain, as evidenced by caliperometry data, which was statistically significant (p 0.05) compared with the control group (20%). In Group 2, muscle gain was observed in 75% of the patients (p 0.05). CONCLUSION: These findings suggest that protein-enriched ONS not only increase BMI but also contribute to muscle mass gain in patients with cystic fibrosis. New therapeutic approaches are needed, such as the inclusion of high-protein ONS in the diet to prevent muscle mass loss, along with the monitoring of body composition to improve control of disease progression.

1 June 2023 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
AAA.I. Asmanov
A.I. Asmanov
NVN.D. Vashakmadze
N.D. Vashakmadze
VVV.A. Vilensky
V.A. Vilensky
VVV.Yu. Voinova
V.Yu. Voinova
IVI.G. Vorontsova
I.G. Vorontsova
MEMoscow Russian Medical Academy For Continuous Professional Education
Moscow Russian Medical Academy For Continuous Professional Education
Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.

5 October 2020 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
FKF. R. Khadzhieva
F. R. Khadzhieva
SMS. N. Mushanova
S. N. Mushanova
TKTatiana Kekeeva
Tatiana Kekeeva
ILI. N. Lavrentyeva
I. N. Lavrentyeva
ERE. V. Raykina
E. V. Raykina
Red cell pyruvate kinase deficiency is a rare congenital, nonspherocytic hemolytic anemia caused by a glycolytic defect that is due to compound heterozygous or homozygous mutations in the PKLR gene on chromosome 1q21. The article presents analytical review of literature and the clinical case of pyruvate kinase deficiency. Patient's parents agreed to use personal dats and photos in research and publications.

5 January 2024 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
TKTatiana Kekeeva
Tatiana Kekeeva
NPN. L. Pechatnikova
N. L. Pechatnikova
IVI. P. Vitkovskaya
I. P. Vitkovskaya
V(Victoria Lobanova (Kakaulina)
Victoria Lobanova (Kakaulina)
NKN. A. Krasnoschekova
N. A. Krasnoschekova
YMYu. E. Martynenko
Yu. E. Martynenko
Duchenne muscular dystrophy (DMD) is an X-linked inherited neuromuscular disorder typically manifesting in boys aged 2–5 years, characterized by a progressive course. According to natural disease progression data, individuals with DMD typically lose the ability to walk independently by the age of 13. In most cases, the disease leads to cardiorespiratory complications, resulting in a lethal outcome between the ages of 20–30.In recent years, there have been therapeutic agents developed for the pathogenic treatment of this condition. One such medication is ataluren (Translarna®), used in patients with DMD caused by the formation of a “stop codon” (nonsense mutation) in the DMD gene, responsible for the development of the disease.This article presents the experience of applying ataluren (Translarna®) in boys residing in Moscow who suffer from Duchenne muscular dystrophy.